Skip to main content
. 2019 Jul 8;51(7):76. doi: 10.1038/s12276-019-0274-7

Fig. 1. HCC cell viability at different concentrations of apatinib and sorafenib, as evaluated by CCK-8 assays and BLI after 24 h of drug administration.

Fig. 1

a CCK-8 assays of the apatinib and (b) sorafenib treatment groups. (c–h) BLI images. (i, j) Quantification of BLI signal intensity